Skip to main content
main-content

Connective tissue diseases

Medications

Add-on omalizumab shows potential for SLE

Preliminary results from a phase Ib trial suggest that add-on treatment with the anti-IgE antibody omalizumab may be a feasible option for patients with systemic lupus erythematosus.

02-01-2019 | Systemic lupus erythematosus | Highlight | News

Add-on omalizumab shows potential for SLE

Preliminary results from a phase Ib trial suggest that add-on treatment with the anti-IgE antibody omalizumab may be a feasible option for patients with systemic lupus erythematosus.

Source:

Arthritis Rheumatol 2018; doi:10.1002/art.40828

14-12-2018 | Pediatric | Article

Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

Jung JY et al. Pediatr Rheumatol 2018; 16: 79. doi: 10.1186/s12969-018-0296-z

11-12-2018 | Systemic lupus erythematosus | Article

New therapeutic strategies in systemic lupus erythematosus management

Gatto M et al. Nat Rev Rheum 2018. doi: 10.1038/s41584-018-0133-2

Ustekinumab shows potential for the treatment of SLE

Ronald van Vollenhoven discusses phase II trial results demonstrating that the interkeukin-12/23 inhibitor ustekinumab may be a promising treatment option for systemic lupus erythematosus (5:36).

24-10-2018 | Systemic lupus erythematosus | ACR/ARHP 2018 | Video

Ustekinumab shows potential for the treatment of SLE

Ronald van Vollenhoven discusses phase II trial results demonstrating that the interkeukin-12/23 inhibitor ustekinumab may be a promising treatment option for systemic lupus erythematosus (5:36).

Vaccination in children and adolescents with rheumatic conditions

In this editorial, the authors discuss the risks of live vaccination in children taking antirheumatic medications and how to manage these, as well as how health authorities can address decreasing vaccination coverage of the general public.

18-10-2018 | Infection | Editorial | Article

Vaccination in children and adolescents with rheumatic conditions

In this editorial, the authors discuss the risks of live vaccination in children taking antirheumatic medications and how to manage these, as well as how health authorities can address decreasing vaccination coverage of the general public.

Author:
NM Wulffraat, AM de Groot, EES Nieuwenhuis

Planning and managing pregnancy in lupus patients

Megan Clowse discusses the importance of planning pregnancy in patients with lupus to avoid high-risk pregnancy, and outlines strategies to manage active lupus during pregnancy.

16-10-2018 | Pregnancy | Editorial | Article

Planning and managing pregnancy in lupus patients

Megan Clowse discusses the importance of planning pregnancy in patients with lupus to avoid high-risk pregnancy, and outlines strategies to manage active lupus during pregnancy.

Author:
Megan EB Clowse

15-09-2018 | Myositis | Review | Article

Current treatment for myositis

Barsotti S, Lundberg IE. Curr Treat Options in Rheum 2018. doi: 10.1007/s40674-018-0106-2

14-08-2018 | Lupus nephritis | Review | Article

Induction therapy for lupus nephritis: The highlights

Ayoub I, Nelson J, Rovin BH. Curr Rheumatol Rep 2018; 20: 60. doi: 10.1007/s11926-018-0766-9

06-08-2018 | Systemic sclerosis | News

Rituximab may improve lung, skin manifestations of SSc

Results of an open-label randomized trial suggest that rituximab may be an appropriate alternative to cyclophosphamide for treating lung and skin disease associated with systemic sclerosis.

Source:

Rheumatology 2018; doi:10.1093/rheumatology/key213

26-07-2018 | Scleroderma | Article

Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: Open label, randomized, controlled trial

Sircar G et al. Rheumatology (Oxford) 2018: key213. doi: 10.1093/rheumatology/key213

11-07-2018 | Pediatric | Review | Article

Pediatric Rheumatology Collaborative Study Group: Over four decades of pivotal clinical drug research in pediatric rheumatology

Brunner HI et al. Pediatr Rheumatol 2018; 16: 45. doi: 10.1186/s12969-018-0261-x

03-07-2018 | Vasculitis | Article

Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: A retrospective observational study

Bae S, Charles-Schoeman C. Clin Rheumatol 2018; 37: 2113–2123. doi: 10.1007/s10067-018-4174-3

image credits